Gillard, Kristin K. http://orcid.org/0000-0003-3342-2878
Bloedon, LeAnne
Grady-Benson, John C.
Edwards, Alison
Fahy, Sean
Sasiela, William J.
Louie, Michael J.
Thompson, Paul D.
Funding for this research was provided by:
Esperion Therapeutics
Article History
Received: 4 March 2024
Accepted: 6 June 2024
First Online: 14 July 2024
Declarations
:
: Paul D. Thompson is on the Study Executive Committee for the CLEAR Outcomes study, funded by Esperion Therapeutics, Inc. He receives research support to his institution from Esperion and Novartis, has consulted for Esperion and Amgen, and owns stock in AbbVie, Abbott Labs, CVS, General Electric, Johnson & Johnson, Medtronic, Sarepta, and Shockwave Medical. LeAnne Bloedon is an employee of Esperion Therapeutics, Inc. Michael J. Louie and Kristin K. Gillard were employees of Esperion Therapeutics, Inc. at the time of the study, and are now employees of UroGen Pharma and Bristol Myers Squibb, respectively. Alison Edwards and Sean Fahy are employees of Symphony Health. John C. Grady-Benson has no relevant conflicts of interest to declare. William J. Sasiela is a current consultant for, and former employee of, Esperion Therapeutics, Inc. and may own stock and/or stock options.
: This study was exempt from independent ethics committee or institutional review board approval as it was a retrospective database study based on the secondary use of anonymous claims data in the United States. Permission was obtained to utilize the database examined in this study. All studies were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.